NRAS and melanoma: Recently, Nagore et al. provided preliminary evidence that in stage I/II melanoma patients TERT promoter status in combination with BRAF/NRAS mutations can be used to identify patients at risk of aggressive disease and the possibility of further prognostic refinement by assessing the rs2853669 polymorphism within TERT promoter [8].